Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer

AIMS: Compare lurbinectedin versus other second-line (2L) small-cell lung cancer (SCLC) treatments. METHODS: An unanchored matching-adjusted indirect comparison connected the platinum-sensitive SCLC cohort of a single-arm lurbinectedin trial to a network of three randomized controlled trials (oral a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanvesakul, Raj, Rengarajan, Badri, Naveh, Navit, Boccuti, Anne, Park, Julie E, Adeyemi, Adekemi, Caisip, Clyde, Jansen, Jeroen P, Wilson, Florence R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Becaris Publishing Ltd 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402758/
https://www.ncbi.nlm.nih.gov/pubmed/37079341
http://dx.doi.org/10.57264/cer-2022-0098
Descripción
Sumario:AIMS: Compare lurbinectedin versus other second-line (2L) small-cell lung cancer (SCLC) treatments. METHODS: An unanchored matching-adjusted indirect comparison connected the platinum-sensitive SCLC cohort of a single-arm lurbinectedin trial to a network of three randomized controlled trials (oral and intravenous [IV] topotecan, and platinum re-challenge) identified by systematic literature review. Network meta-analysis methods estimated relative treatment effects. RESULTS: In platinum-sensitive patients, lurbinectedin demonstrated a survival benefit and favorable safety profile versus oral and IV topotecan and platinum re-challenge (overall survival, hazard ratio [HR]: 0.43; 95% credible interval [CrI]: 0.27, 0.67; HR: 0.43; 95% CrI: 0.26, 0.70; HR: 0.42; 95% CrI: 0.30, 0.58 respectively). CONCLUSION: Lurbinectedin showed a robust survival benefit and favorable safety versus other SCLC treatments in 2L platinum-sensitive SCLC.

Ejemplares similares